This concept led to a substantial reduction of the LDL-C goals recommended by the most recent guidelines for the management of dyslipidemias (Mach et al. 2020). Statins, which represent the cornerstone for the treatment of hypercholesterolemia, have shown approximately a 20% reduction in the ...
These changes should further lower total and LDL-C concentrations nationally.Hypothesis: We hypothesized that LDL-C blood values would decline following the 2013 ACC/AHA guidelines due to an expanded population eligible for statin treatment.Methods: We examined 507,752 patients nationally aged ≥16 ...
Importantly, and not unlike the ACC/AHA guidelines, statin therapy is the go-to treatment for elevated cholesterol, with the ESC/EAS recommending the highest dose tolerable to achieve treatment goals (class I, level of evidence A). For patients who are statin intolerant, ezetimibe (Zetia, ...
The publication of these data directly challenge the direction the 2013 ACC/AHA guidelines. These data suggest that LDL-C values on treatment are more noteworthy in post-ACS patients and that LDL-C treatment goals should be both measured and acted upon in post-ACS patients. It is clear that...
The 2013 ACC/AHA guidelines focus on statin intensity instead of LDL-C goals and suggest intensive treatment of elevated LDL-C among ASCVD patients. Duration of exposure to elevated LDL-C has been shown to increase risk of CV events demonstrating an urgency to lower uncontrolled LDL-C. The go...
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143–52. https://doi.org/10.1093/eurheartj/ehr080. Article PubMed PubMed Central Google Scholar Kotseva K, De Backer G, De Bacquer ...
Among current and former statin users, 31‒58% knew the treatment aims (primary or secondary prevention of CVDs) and only approximately half were aware of cholesterol treatment goals, of which 49% and 72% could not name a numerical value for total cholesterol and LDL-C, respectively32. ...
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering the...
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Athero- sclerotic Vascular Disease: 2006 Update. J Am Coll Cardiol. 2006;47: 2130–2139. 6. Executive Summary: Standards of Medical Care in Diabetes – 2009. Diabetes Care. 2009;32 Suppl 1:s6–s12. 10 Powered ...
According to the 2013 ACC/AHA Cholesterol Guidelines, nonstatin therapy may be considered for individuals with severe hypercholesterolemia, those who are at higher risk but unable to tolerate high-intensity statin therapy, or those in need of additional LDL-C lowering.2 Nonstatin LDL-C–lowering ...